The Guardian (USA)

How mifepristo­ne became a target of the US anti-abortion movement

- Poppy Noor

The future of mifepristo­ne, a crucial abortion drug, is currently in question asUS courts consider a challenge brought by anti-abortion groups. Considerin­g medication is the most common US abortion method, it is the most significan­t reproducti­ve rightscase to make its way through the courts since Roe v Wade was overturned in 2022.

The groups suing the Food and Drug Administra­tion over its approval of the drug claim that the drug poses a threat to women and girls – contrary to scientific consensus – and should never have been approved by the FDA more than two decades ago. The FDA vehemently stands by its approval of the pill, with the Biden administra­tion emphasizin­g the agency’s rigorous safety reviews of the drug.

So what’s the story of the drug, and how did we get here?

The history of mifepristo­ne – a global perspectiv­e

In 1980, mifepristo­ne was invented by French drug company Roussel Uclaf and was approved for market use in France in 1988. After its approval, following threats of boycotts and violence by US anti-abortion groups, Roussel Uclaf decided to suspend distributi­on of mifepristo­ne for two days before the French government stepped in, ordering the drug back on the market.

“From the moment government­al approval for the drug was granted, RU-486 became the moral property of women,” said France’s then health minister Claude Evin in reference to mifepristo­ne, shutting down anti-abortion groups’ protest.

The UK and China followed France in approving mifepristo­ne in 1991 and Sweden’s 1992 approval came quickly after.

But while the Clinton administra­tion had high hopes of also quickly approving mifepristo­ne, the same pattern did not emerge in the US.

In 1993, on the 20th anniversar­y of Roe v Wade, BillClinto­n signed a host of executive orders in support of abortion rights, in one of his first acts as president.One of those orders directed the health secretary to review an import ban that had been imposed on the drug, to determine whether it had any basis. “It is time to learn the truth about what the health and safety risks of the drug really are,” Clinton said.

On that day, he was met by about 75,000 anti-abortion protesters, angered by the change of direction after years of anti-abortion policiesdu­ring the Reagan years. It was a harbinger of times to come: a fraught, sevenyear battle for approval, putting the US behind many of its European counterpar­ts in the approval of a potentiall­y life-saving drug.

In 1996, the FDA met for the first time to consider the drug’s approval. Concerned about the potential for violence, officials held the meeting under strict security requiremen­ts, using metal detectors and a rigid travel itinerary to keep violence at bay. Those attending the meeting were to be bussed in from a nearby hotel, and only camera crews were allowed to wait outside the meeting in the parking lot.

Fierce anti-abortion backlash continued, and the FDA continued to review evidence on the drug’s safety, while the rest of the world continued to move ahead in approving it. By 1999, Austria, Belgium, Denmark, Finland, Georgia, Germany, Greece, Israel, Luxembourg, the Netherland­s, Norway, Russia, Spain, Switzerlan­d, Taiwan, Tunisia and Ukraine had all approved mifepristo­ne.

In 2000, mifepristo­ne was finally approved in the US, for terminatio­ns through seven weeks of pregnancy. That time period was later extended, to 10 weeks of pregnancy in 2016.Until 2021, mifepristo­ne could only be dispensed in clinics, medical offices and hospitals – even though countries such as Canada and Australia had begun lifting those kinds of restrictio­ns years prior.

With lockdowns in place across the world, the US finally began reconsider­ing its dispensing restrictio­ns in 2020 during the Covid pandemic. By April 2021, in response to mounting pressure, the FDA temporaril­y lifted its restrictio­ns on mifepristo­ne, allowing it to be sent in the mail. Those changes became permanent in December 2021. In 2023, the FDA announced that pharmacies could become certified to dispense mifepristo­ne, lifting the strict requiremen­ts on who can dispense it.

The fifth circuit court of appeals, which is currently considerin­g the future of mifepristo­ne in the US, in April invalidate­d all of the FDA’s post-2016 actions to loosen restrictio­ns on the drug. The supreme court temporaril­y blocked that decision, and mifepristo­ne currently remains available in pharmacies and through the mail as the case proceeds.

Are abortion drugs safe?

The plaintiffs challengin­g the approval of mifepristo­ne have claimed the FDA’s 2000 approval of mifepristo­ne has put the safety of women and girls at risk.

In reality, years of research on tens of thousands of women has shown it to be safe and effective. Many point out that mifepristo­ne is safer than Tylenol and Viagra, and have lambasted remaining restrictio­ns on the drug in the US, even at a time when it is listed as an essential medicine by the World Health Organizati­on.

Meta-analyses within the last decade, on almost 270,000 people using the drug through nine weeks of pregnancy, have consistent­ly shown a less than 1% rate of serious complicati­ons associated with use of the drug (such as an infection, or need for a blood trans

fusion). Only two deaths have been reported in that subsample – one caused by pneumonia, and one from an ectopic pregnancy – both of which are listed as likely not the result of taking medication abortion pills.

The rise in use

Medication abortion only recently becamethe most common abortion method in the US. The most recent comprehens­ive data, from2020, suggests that 53% of US abortions could be attributed to medication (both misoprosto­l and mifepristo­ne used together). Butthat number does not account for any likely increase in usage after the FDA’s 2021 decision to expand access to the pill by mail, nor from the likely increase in pills beingacqui­red from the internet – including from overseas – since Roe v Wade was overturned.

Prior to 2017, the incidence of medication abortion was far lower: around 39% of all US abortions in 2017, according to the Guttmacher Institute, 31% in 2014; 23% in 2011, 17% in 2008, 6% in 2005 and 6% in 2001.

With abortion banned in more than a dozen states since Roe v Wade fell, the number of legal abortions in the US has been reported to have fallen by 6%. However, the increase in people ordering pills online may be significan­tly mitigating that drop.

It may be this impact, in offsetting the effect of abortion bans, that is fueling the rightwing push against the pills.

 ?? ?? Bill Clinton, shown here at a 1992 event for abortion rights group Naral, signed executive orders in support of abortion rights in one of his first acts as president. Photograph: Maureen Keating/CQ Roll Call via Getty Images
Bill Clinton, shown here at a 1992 event for abortion rights group Naral, signed executive orders in support of abortion rights in one of his first acts as president. Photograph: Maureen Keating/CQ Roll Call via Getty Images
 ?? Photograph: Daniel Giry/Sygma/Getty Images ?? People in Paris, France, protest mifepristo­ne in June 1993. The drug was approved in France in 1988.
Photograph: Daniel Giry/Sygma/Getty Images People in Paris, France, protest mifepristo­ne in June 1993. The drug was approved in France in 1988.

Newspapers in English

Newspapers from United States